Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Significant improvement of bone marrow fibrosis in patients with chronic myeloproliferative neoplasms (CMPN) treated with ruxolitinib.

View Full Paper
Ask AI
Bookmark
Share

Authors

PVPablo Vargas ViverosRMRafael Hurtado MonroyDEDiana Mendoza Elizarraraz

Discussion

Loading...

Member takes

Overview

Analysis reveals ruxolitinib significantly lowers myelofibrosis grades in CMPN patients, suggesting enhanced survival rates.

Key Points

  • To assess the impact of long-term ruxolitinib treatment on bone marrow fibrosis in CMPN patients.
  • Analyzed bone marrow biopsies from 16 CMPN patients over a median follow-up of 10 years.
  • Patients received 20 mg of ruxolitinib orally every 12 hours.
  • Biopsies were evaluated before treatment and after 10 years.
  • Six patients improved from fibrosis grade 3 to grade 1, mostly with thrombocythemia and polycythemia.
  • Five patients with fibrosis grade 2 showed minimal fibrosis after treatment, all with thrombocythemia.
  • Five patients maintained stable fibrosis, including four with primary myelofibrosis.

Cite This Study

Viveros et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6bbhttps://doi.org/10.1182/blood-2025-7333
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study2024 · 1 citations
  2. 2A case report of ruxolitinib reversing myelofibrosis2025
  3. 3Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study2025 · 5 citations
  4. 4Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.2024
  5. 5Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls2012 · 218 citations